Clinical Trial Update: Sidlenafil in Combination With Oral Anticoagulants in Patients With Intermediate-high Risk of Pulmonary Embolism [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update evaluating sildenafil in combination with oral anticoagulants for patients with intermediate-high-risk pulmonary embolism.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Embolism

Drugs mentioned

• SILDENAFIL (SILDENAFIL)

Snippet

Sponsor: Meshalkin Research Institute of Pathology of Circulation | Conditions: Pulmonary Embolism, Intermediate-high Risk | Phase 1 | Status: UNKNOWN